Abstract: A halogen-free, flame retardant composition comprises: A. A polymer blend comprising: 1. Polypropylene, and 2. Thermoplastic elastomer (TPE) other than the polypropylene of (A)(1), and B. An intumescent flame retardant comprising at least one of: 1. A compound of Formula 1 where M is at least one of melamine, morpholine, piperazine, piperidine, alkyl hydroxyl and a triazine polymer of Formula 2 where D is a heterocyclic or polyamine moiety, and m and n are independently integers the sum (m+n) of which is less than 1000, and 2. A piperazine phosphate.

Abstract: A halogen-free, flame retardant composition comprises: A. A polymer blend comprising: 1. Polypropylene, and 2. Thermoplastic elastomer (TPE) other than the polypropylene of (A)(1), and B. An intumescent flame retardant comprising at least one of: 1. A compound of Formula 1 where M is at least one of melamine, morpholine, piperazine, piperidine, alkyl hydroxyl and a triazine polymer of Formula 2 where D is a heterocyclic or polyamine moiety, and m and n are independently integers the sum (m+n) of which is less than 1000, and 2. A piperazine phosphate.

Abstract: Compositions comprising a novolac polymer, an olefin-based polymer with an epoxy group, a filler and optionally a thermoplastic polymer are provided. The compositions may be halogen-free. The present compositions exhibit excellent compatibility between the novolac polymer and the olefin-based polymer with an epoxy group resulting in compositions with superior mechanical properties.

Abstract: Compositions comprising a novolac polymer, an olefin-based polymer with an epoxy group, a filler and optionally a thermoplastic polymer are provided. The compositions may be halogen-free. The present compositions exhibit excellent compatibility between the novolac polymer and the olefin-based polymer with an epoxy group resulting in compositions with superior mechanical properties.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: The present invention provides a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule; the fill material comprises (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a primary or secondary amine compound in an amount sufficient to inhibit cross-linking of gelatin in said gelatin capsule upon storage of the dosage form in a closed container maintained at 40° C. and 75% relative humidity for a period of 6 months.

Abstract: A novel method is provided for enhancing dispersion of drug-containing particles in an aqueous medium. According to this method, a solid dosage form of the drug is provided having incorporated therein a dispersion-enhancing amount of an effervescent agent wherein (a) the dosage form is adapted for swallowing without prior disintegration in water or in the mouth, and (b) the amount of the effervescent agent is not sufficient to substantially enhance disintegration of the dosage form in the aqueous medium.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.